QuantHealth, an AI-based clinical trial design company, announced it has surpassed 100 successfully simulated clinical trials, achieving 85% accuracy and a major return on investment (ROI) for pharmaceutical partners.
The company utilizes proprietary technology and patient-centric solutions to resolve the pervasive issue of trial failures. Historically, 90% of clinical trials fail due to suboptimal protocol design, inefficiencies, and safety concerns. And with drug development taking 10 to 15 years and costing nearly $1 billion per drug, most candidates fail to reach approval. To handle these challenges, QuantHealth’s Clinical-Simulator forecasts individual patient responses within clinical trials, empowering design teams to anticipate overall trial dynamics and adjust strategies accordingly.
In partnership with one pharmaceutical company’s respiratory disease team, QuantHealth also enabled cost reductions of more than $215 million and significantly improved the likelihood of trial success. Utilizing data from 350 million patients and 700,000 drug entities, its advanced analytics module simulated over 5,000 protocol variations within minutes to identify which factors most likely contributed to success.
Out of more than 30 positive protocols, it then determined the protocol with the highest odds of technical success. Through this process, QuantHealth reduced study duration by 11 months, clinical trial subjects by 251, and full-time employees by 1.5 individuals, resulting in financial returns of $15 million, $200 million, and $385,000, respectively.
QuantHealth’s accuracy outcomes exceeded national averages for Phase II and III, highlighting the power of AI-generated clinical trials.
Accuracy by Therapeutic Area
58.3% better Oncology rates – 88% compared to the national rate of 29.7%
37.8% better Immune & Inflammation rates – 80% compared to the national rate of 42.2%
41.4% better Gastroenterology rates – 83% compared to the national rate of 41.6%
52.6% better Respiratory rates – 84% compared to the national rate of 31.4%
Accuracy by Trial Phase
59.1% better Phase 2 rates – 88% compared to the national rate of 28.9%
25.4% better Phase 3 rates – 83.2% compared to the national rate of 57.8%
KEY QUOTE:
“Being at the forefront of AI-enabled clinical trials for nearly a decade, it’s astounding to see how much progress has been made and the promise that AI holds for clinical trial improvement. Once seen as science fiction, our technology has proven to safely and accurately predict the results of clinical trials and now has significant traction. We currently have five of the top 20 pharmaceutical companies on board, and with this number expected to double by next year, we look forward to addressing the core issue of trial failures at scale, and continuing to meet market needs swiftly and effectively.”
- Orr Inbar, CEO and Co-Founder of QuantHealth
